#USA #Los Angeles #Securities Fraud #MoonLake #MLTX

MoonLake Immunotherapeutics Shareholders: Join the Fight Against Securities Fraud

In a recent development, Glancy Prongay & Murray LLP has announced a critical opportunity for shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) who have suffered financial losses. Investors can now step forward to lead a class action lawsuit accusing the company of securities fraud. This announcement has been made public as of December 1, 2025, and urges affected investors to take action before a looming deadline.

What Does This Mean for Investors?

This class action lawsuit centers around significant allegations against MoonLake Immunotherapeutics. The complaint claims that, between March 10, 2024, and September 29, 2025, the company and its executives failed to disclose crucial information to the shareholders. The allegations include the following points:

• - The molecular targets for SLK and BIMZELX are identical, namely the inflammatory cytokines IL-17A and IL-17F, which raises concerns about the differentiated claims made for SLK's new therapeutic approach.
• - The company touted the distinct Nanobody structure of SLK as beneficial, implying superior clinical efficacy over the traditional monoclonal structure used by BIMZELX. However, the complaint argues that this assertion is fundamentally flawed.
• - Furthermore, investors were misled by claims that SLK's supposed increased tissue penetration would correspond with tangible clinical efficiency, a statement the lawsuit contests.
• - Ultimately, the lawsuit asserts that the positive remarks regarding the company's business operations and prospects were misleading and lacked a reasonable basis.

How Affected Shareholders Can Join the Lawsuit

If you are a shareholder who has incurred losses from investments in MoonLake, this is your chance to be a part of a significant collective action. The law firm has provided an invitation to join the lawsuit before the December 15, 2025, deadline, when the lead plaintiff application close. Interested investors are encouraged to reach out for more details about how to join or learn more about the case's progress.

To Participate or Learn More

If you want to explore this class action lawsuit further or have any questions regarding your rights as an investor, please contact:

• - Charles Linehan

Glancy Prongay & Murray LLP
1925 Century Park East, Suite 2100
Los Angeles, California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Website: www.glancylaw.com

No immediate actions are required from investors who wish to remain absent members of the class action, although consultation with a legal advisor is advisable to understand your options.

As the legal proceedings unfold, updates and key announcements will be made available via the law firm's official channels, including LinkedIn, Twitter, and Facebook. Shareholders are urged to stay informed about their rights and the ongoing developments within this case. This situation serves as a stark reminder of the complexities and potential pitfalls inherent in financial investments—underscoring the importance of rigorous oversight and vigilance among investors.